DOCSLIB.ORG

Factor V Leiden Inherited Prothrombin 20210A Protein C Deficiency Prothrombotic Protein S Deficiency Mutation(S) Antithrombin Deficiency

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Factor V Leiden Inherited Prothrombin 20210A Protein C Deficiency Prothrombotic Protein S Deficiency Mutation(S) Antithrombin Deficiency ThrombophiliaThrombophilia DiagnosisDiagnosis andand ManagementManagement Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri Thrombophilia • Hereditary and acquired risk factors for thrombosis • Venous thromboembolism • Arterial thromboembolism • Pregnancy complications Virchow’s Triad 1850 Vessel Wall Altered Blood Flow Damage Factors (Stasis) Contributing to Thrombosis Blood Coagulability One or more Factor V Leiden Inherited Prothrombin 20210A Protein C deficiency Prothrombotic Protein S deficiency Mutation(s) Antithrombin deficiency Thrombosis Acquired Antiphospholipid antibodies Malignancy Prothrombotic Immobilization Stimulus Surgery Pregnancy Estrogen Hyperhomocysteinemia After Schafer Heparin-induced thrombocytopenia Prevalence of Hereditary Risk Factors in Venous Thromboembolism (VTE) Asymptomatic Unselected Familial Mutation (N) Controls VTE VTE Factor V Leiden (1) 4% 20% 45% Prothrombin 20210A (1) 2% 6% 18% Protein C (>160) 0.8% 3% 6% Protein S (>13) 0.5% 1% 6% Antithrombin (>80) 0.2% 1% 4% (All Autosomal Dominant) Factor V Leiden •Most common hereditary risk factor for venous thrombosis •Present in 4% of Caucasian population •Caused by a point mutation in Factor V (R506Q) •Poor anticoagulant response to activated protein C (APC Resistance) The Protein C Anticoagulant Pathway Blood Flow Protein C Thrombin Thrombin APC Thrombomodulin Thrombus Anticoagulation Thrombus downstream at site of injury The Protein C Anticoagulant Pathway Blood Flow Vai Factor V Leiden VIIIai VIIIa Va APC APC PS PS Thrombus Activated Protein C Resistance 3 Control APTT 2 Ratio 1 Factor V Leiden 0 12345 APC (µg/ml) Prothrombin Gene Mutation • Second most common hereditary risk factor for venous thrombosis • Present in 2% of Caucasian population • Caused by a point mutation (G20210A) in the 3’ UTR of prothrombin gene • Elevated levels of prothrombin in plasma Antithrombin Deficiency • Antithrombin (also called AT III) inhibits thrombin, factor Xa and other clotting factors • Activity enhanced by heparin • Risk factor for venous thrombosis, especially during pregnancy Influence of Hereditary Risk Factors on Probability of First DVT or PE Risk Factor Relative Risk General population 1 Heterozygous factor V Leiden 5 Heterozygous prothrombin 20210A 5 Protein C deficiency ∼10 Protein S deficiency ∼10 Antithrombin deficiency ∼20 Homozygous factor V Leiden ∼80 Influence of Hereditary Risk Factors on Probability of First DVT or PE 100 general population (RR=1) 80 heterozygous FVL (RR=5) 60 protein C def (RR=10) 40 antithrombin def (RR=20) 20 homozygous FVL (RR=80) 0 Thrombosis-free Survival (%) Survival Thrombosis-free 0 20406080 Age (years) After Miletich (1998) Semin Thromb Hemost Influence of Acquired Risk Factors on Probability of First DVT or PE Risk Factor Relative Risk General population 1 Hyperhomocysteinemia 2 Estrogen therapy 4 Active cancer ~7 Lupus anticoagulant or antiphospholipid antibody ~10 Hyperhomocysteinemia • Elevated level of homocysteine in plasma • Multiple causes Genetic factors – uncommon Nutritional factors (folate, B12, B6) – common Renal dysfunction – common • Cardiovascular disease, stroke, peripheral vascular disease • Neural tube defects • Dementia Treatment of Hyperhomocysteinemia •Folic acid Foltx® •Other B vitamins (B12, B6) •Methionine restriction Antiphospholipid Antibodies Lupus Anticardiolipin Anticoagulants Antibodies Clinically-Important APLA Clinically Important Antiphospholipid Antibodies •High titer (>30 GPL or MPL) anticardiolipin antibodies (IgG or IgM) •Lupus anticoagulant •Systemic lupus erythematosus or lupus-like syndrome Management of Patients with Antiphospholipid Antibodies •Chronic anticoagulation not necessary if no history of thrombosis •Long-term anticoagulation with warfarin after first thrombotic event Target INR 2-3 (hematologists) Target INR 3-4 (rheumatologists) •Some antiphospholipid antibodies interfere with INR (may need higher target INR or alternative method to monitor anticoagulation) Influence of Combinations of Risk Factors on Probability of First DVT/PE Risk Factor Relative Risk General population 1 Hyperhomocysteinemia 2 Heterozygous factor V Leiden 5 Hyperhomocysteinemia and heterozygous factor V Leiden 20 Influence of Combinations of Risk Factors on Probability of First DVT or PE Risk Factor Relative Risk General population 1 Oral contraceptives 4 Heterozygous factor V Leiden 5 Oral contraceptives and heterozygous factor V Leiden 35 Influence of Oral Contraceptives and Factor V Leiden on Probability of First DVT or PE 100 general population (RR=1) oral contraceptives (RR=4) pregnancy (RR=10) 90 oral contraceptives and heterozygous FVL (RR=35) 80 Thrombosis-free Survival (%) 15 20 25 30 35 40 Age (years) Hereditary Risk Factors and Arterial Thrombosis (Stroke or MI) Risk Factor Relative Risk Heterozygous Factor V Leiden 1 Heterozygous Prothrombin 20210A 1 Protein S deficiency 1 Protein C deficiency 1 Antithrombin deficiency 1 Possible exception: young patients, especially in association with smoking or hypertension Other Putative Risk Factors (Not Ready for Prime Time) • Fibrinogen • GPIa C807T • Lipoprotein (a) • GPIIIa PLA2 • Factor VIII • PAI-1 4G/5G • Von Willebrand factor • D-dimer • Thrombomodulin • TFPI • Heparin Cofactor II • MTHFR • Factor XII • Protein Z Laboratory Testing for Thrombophilia • Factor V Leiden • Prothrombin 20210A gene mutation • Anticardiolipin antibodies • Lupus anticoagulant workup • Plasma total homocysteine • Antithrombin (not reliable in patients receiving heparin) OtherOther TestsTests toto ConsiderConsider inin ConvalescentConvalescent PeriodPeriod • Protein C • Protein S • These tests are not reliable in acute setting or in patients receiving warfarin Rationale for Thrombophilia Testing • Prophylactic anticoagulation during high risk situations (surgery, pregnancy, immobilization) • Extended duration of anticoagulation after a thrombotic event Antiphospholipid antibody Antithrombin deficiency Two or more thrombophilic alleles (Factor V Leiden, Prothrombin 20210A, Protein C deficiency, Protein S deficiency) • Family genetic counseling Probability of Recurrence After First DVT or PE Relative Risk Temporary risk factor 1 Heterozygous factor V Leiden 2 Homozygous factor V Leiden 4 Antiphospholipid antibody 4 Unprovoked DVT or PE 8 Recurrent DVT or PE 8 Active Cancer 8 Recurrence after First DVT or PE 30 Recurrent 20 DVT/PE unprovoked (%) 10 warfarin temporary risk factor 100 200 300 Days Levine et al. Thromb Haemost 1995; 74:606 Duration of Anticoagulation for First Unprovoked DVT 30 3 months (INR 2-3) 12 months (INR 2-3) 20 Indefinite (INR 1.5-2) 10 Recurrence (%) Indefinite (INR 2-3) 123 Years MyMy ApproachApproach toto PreventionPrevention ofof RecurrentRecurrent VenousVenous ThromboembolismThromboembolism • Low Risk (anticoagulate for 6 weeks to 3 months) Superficial venous thrombosis Secondary DVT or PE • Intermediate Risk (anticoagulate for at least 3 to 6 months; consider indefinite anticoagulation at INR 1.5-2 or 2-3) Unprovoked DVT or PE Unprovoked DVT or PE with one genetic risk factor • High Risk (anticoagulate indefinitely at target INR 2-3) Recurrent unprovoked DVT or PE Life-threatening venous thrombosis Unprovoked DVT or PE with antiphospholipid antibody, two or more genetic risk factors, or active cancer References Kearon et al. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 51:169-185, 2000 Kupferminc, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. New Eng J Med 340:9-13, 1999 Gerhardt, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the peurperium. New Eng J Med 342:374-380, 2000 Gordy et al. American College of Medical Genetics Consensus Statement on Factor V Leiden mutation testing. Genetics in Medicine 3:139-148, 2001 Ridker et al. Long-term low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. New Eng J Med 348:1425-1434, 2003 Lopez et al. Deep venous thrombosis. American Society of Hematology Education Book, 2004.
Load more

Recommended publications
  • Disseminated Intravascular Coagulation (DIC) and Thrombosis: the Critical Role of the Lab Paul Riley, Phd, MBA, Diagnostica Stago, Inc
    Generate Knowledge Disseminated Intravascular Coagulation (DIC) and Thrombosis: The Critical Role of the Lab Paul Riley, PhD, MBA, Diagnostica Stago, Inc. Learning Objectives Describe the basic pathophysiology of DIC Demonstrate a diagnostic and management approach for DIC Compare markers of thrombin & plasmin generation in DIC, including D-Dimer, fibrin monomers (FM; aka soluble fibrin monomers, SFM), and fibrin degradation products (FDPs; aka fibrin split products, FSPs) Correlate DIC theory and testing to specific clinical cases DIC = Death is Coming What is Hemostasis? Blood Circulation Occurs through blood vessels ARTERIES The heart pumps the blood Arteries carry oxygenated blood away from the heart under high pressure VEINS Veins carry de-oxygenated blood back to the heart under low pressure Hemostasis The mechanism that maintains blood fluidity Keeps a balance between bleeding and clotting 2 major roles Stop bleeding by repairing holes in blood vessels Clean up the inside of blood vessels Removes temporary clot that stopped bleeding Sweeps off needless deposits that may cause blood flow blockages Two Major Diseases Linked to Hemostatic Abnormalities Bleeding = Hemorrhage Blood clot = Thrombosis Physiology of Hemostasis Wound Sealing break in vesselEFFRAC PRIMARY PLASMATIC HEMOSTASIS COAGULATION strong clot wound sealing blood FIBRINOLYSIS flow ± stopped clot destruction The Three Steps of Hemostasis Primary Hemostasis Interaction between vessel wall, platelets and adhesive proteins platelet clot Coagulation Consolidation
    [Show full text]
  • Activated Protein C Resistance: the Most Common Risk Factor for Venous Thromboembolism
    J Am Board Fam Pract: first published as 10.3122/15572625-13-2-111 on 1 March 2000. Downloaded from CLINICAL REVIEW Activated Protein C Resistance: The Most Common Risk Factor for Venous Thromboembolism Dawn R. Sheppard, DO Background: Venous thromboembolism is a major cause of morbidity and mortality. Although activated protein C resistance (APC-R) is the most commonly recognized inherited risk factor for venous throm­ boembolism, little is known about its long-tenn implications on health. Methods: MEDLINE was searched from January 1989 through August 1999 using the key words ''thromboembolism," ''thrombosis," "activated protein C resistance," and "factor V Leiden." Results: One in 1000 people in the United States is affected by venous thromboembolism annually. APC-R is now understood to be responsible for up to 64% of these cases. APC-R, which occurs widely in some ethnic groups and is nearly absent in others, is due to a single point mutation in the gene for clot­ ting factor V. As a result, inactivation of factor V by activated protein C is impaired, leading to a hyper­ coagulable state. This condition creates a lifelong increased risk of thrombosis and, possibly, anticoag- ulant therapy.. Conclusion: Family physicians have a new tool for assessing risks for venous thromboembolism. Recognizing that up to 64% of patients with venous thromboembolism can have APe-R and treating this disorder with prophylactic and therapeutic anticoagulation might reduce patient morbidity and mortal­ ity from venous thromboembolism. Screening high-risk patients might now be indicated. (J Am Board Fam Pract 2000i13:111-5.) Venous thromboembolism, a serious health prob­ "thromboembolism," "thrombosis," "activated pro­ lem and an important cause of morbidity, affects tein C resistance," and "factor V Leiden." about 1 in 1000 persons annually.
    [Show full text]
  • Familial Multiple Coagulation Factor Deficiencies
    Journal of Clinical Medicine Article Familial Multiple Coagulation Factor Deficiencies (FMCFDs) in a Large Cohort of Patients—A Single-Center Experience in Genetic Diagnosis Barbara Preisler 1,†, Behnaz Pezeshkpoor 1,† , Atanas Banchev 2 , Ronald Fischer 3, Barbara Zieger 4, Ute Scholz 5, Heiko Rühl 1, Bettina Kemkes-Matthes 6, Ursula Schmitt 7, Antje Redlich 8 , Sule Unal 9 , Hans-Jürgen Laws 10, Martin Olivieri 11 , Johannes Oldenburg 1 and Anna Pavlova 1,* 1 Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, 53127 Bonn, Germany; [email protected] (B.P.); [email protected] (B.P.); [email protected] (H.R.); [email protected] (J.O.) 2 Department of Paediatric Haematology and Oncology, University Hospital “Tzaritza Giovanna—ISUL”, 1527 Sofia, Bulgaria; [email protected] 3 Hemophilia Care Center, SRH Kurpfalzkrankenhaus Heidelberg, 69123 Heidelberg, Germany; ronald.fi[email protected] 4 Department of Pediatrics and Adolescent Medicine, University Medical Center–University of Freiburg, 79106 Freiburg, Germany; [email protected] 5 Center of Hemostasis, MVZ Labor Leipzig, 04289 Leipzig, Germany; [email protected] 6 Hemostasis Center, Justus Liebig University Giessen, 35392 Giessen, Germany; [email protected] 7 Center of Hemostasis Berlin, 10789 Berlin-Schöneberg, Germany; [email protected] 8 Pediatric Oncology Department, Otto von Guericke University Children’s Hospital Magdeburg, 39120 Magdeburg, Germany; [email protected] 9 Division of Pediatric Hematology Ankara, Hacettepe University, 06100 Ankara, Turkey; Citation: Preisler, B.; Pezeshkpoor, [email protected] B.; Banchev, A.; Fischer, R.; Zieger, B.; 10 Department of Pediatric Oncology, Hematology and Clinical Immunology, University of Duesseldorf, Scholz, U.; Rühl, H.; Kemkes-Matthes, 40225 Duesseldorf, Germany; [email protected] B.; Schmitt, U.; Redlich, A.; et al.
    [Show full text]
  • Regulation of Coagulation by the Fibrinolytic System: Expecting the Unexpected
    Bleeding disorders Regulation of coagulation by the fibrinolytic system: expecting the unexpected K.A. Hajjar ABSTRACT Department of Cell and Recent investigations into fibrinolysis and coagulation have yielded exciting and unexpected findings. Developmental Biology, Of note, deficiencies of the major components of the classical fibrinolytic system, namely plasminogen, Department of Pediatrics tissue plasminogen activator, and urokinase, are now recognized to be rare causes of macrovascular Department of Medicine, thrombosis. At the same time, both plasminogen activator excess and fibrinolytic inhibitor deficiencies Weill Cornell Medical College, are associated with clinically significant bleeding, while elevated inhibitor levels, particularly thrombin New York, New York, USA activatable fibrinolysis inhibitor, appear to confer clinically significant risk for thrombosis. Receptor- mediated cell surface fibrinolysis adds a new dimension to the regulation of fibrin balance. Exaggerated expression of the annexin A2 complex, for example, is associated with hemorrhage in acute promyelo- Hematology Education: cytic leukemia, whereas autoantibodies directed against A2 correlate with thrombotic disease in the education program for the patients with antiphospholipid syndrome. The contributions of the urokinase receptor and a diverse annual congress of the European array of plasminogen receptors to fibrin homeostasis remain to be defined. Future studies are likely to Hematology Association reveal novel mechanisms that co-regulate coagulation and
    [Show full text]
  • Heart – Thrombus
    Heart – Thrombus Figure Legend: Figure 1 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study. A thrombus is present in the right atrium (arrow). Figure 2 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study (higher magnification of Figure 1). Multiple layers of fibrin, erythrocytes, and scattered inflammatory cells (arrows) comprise this right atrial thrombus. Figure 3 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study. A large thrombus with two foci of mineral fills the left atrium (arrow). Figure 4 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study (higher magnification of Figure 3). This thrombus in the left atrium (arrows) has two dark, basophilic areas of mineral (arrowheads). 1 Heart – Thrombus Comment: Although thrombi can be seen in the right (Figure 1 and Figure 2) or left (Figure 3 and Figure 4) atrium, the most common site of spontaneously occurring and chemically induced thrombi is the left atrium. In acute situations, the lumen is distended by a mass of laminated fibrin layers, leukocytes, and red blood cells. In more chronic cases, there is more organization of the thrombus (e.g., presence of vascularized fibrous connective tissue, inflammation, and/or cartilage metaplasia), with potential attachment to the atrial wall. Spontaneous rates of cardiac thrombi were determined for control Fischer 344 rats and B6C3F1 mice: in 90-day studies, 0% in rats and mice; in 2-year studies, 0.7% in both genders of mice, 4% in male rats, and 1% in female rats.
    [Show full text]
  • Thrombotic Thrombocytopenic Purpura
    Thrombotic thrombocytopenic Purpura Flora Peyvandi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca’ Granda Ospedale Maggiore Policlinico University of Milan Milan, Italy Disclosures Research Support/P.I. No relevant conflicts of interest to declare Employee No relevant conflicts of interest to declare Consultant Kedrion, Octapharma Major Stockholder No relevant conflicts of interest to declare Speakers Bureau Shire, Alnylam Honoraria No relevant conflicts of interest to declare Scientific Advisory Ablynx, Shire, Roche Board Objectives • Advances in understanding the pathogenetic mechanisms and the resulting clinical implications in TTP • Which tests need to be done for diagnosis of congenital and acquired TTP • Standard and novel therapies for congenital and acquired TTP • Potential predictive markers of relapse and implications on patient management during remission Thrombotic Thrombocytopenic Purpura (TTP) First described in 1924 by Moschcowitz, TTP is a thrombotic microangiopathy characterized by: • Disseminated formation of platelet- rich thrombi in the microvasculature → Tissue ischemia with neurological, myocardial, renal signs & symptoms • Platelets consumption → Severe thrombocytopenia • Red blood cell fragmentation → Hemolytic anemia TTP epidemiology • Acute onset • Rare: 5-11 cases / million people / year • Two forms: congenital (<5%), acquired (>95%) • M:F ratio 1:3 • Peak of incidence: III-IV decades • Mortality reduced from 90% to 10-20% with appropriate therapy • Risk of recurrence: 30-35% Peyvandi et al, Haematologica 2010 TTP clinical features Bleeding 33 patients with ≥ 3 acute episodes + Thrombosis “Old” diagnostic pentad: • Microangiopathic hemolytic anemia • Thrombocytopenia • Fluctuating neurologic signs • Fever • Renal impairment ScullyLotta et et al, al, BJH BJH 20122010 TTP pathophysiology • Caused by ADAMTS13 deficiency (A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motifs, member 13) • ADAMTS13 cleaves the VWF subunit at the Tyr1605–Met1606 peptide bond in the A2 domain Furlan M, et al.
    [Show full text]
  • Alpha-Dystroglycan Plays Functional Roles in Platelet Aggregation and Thrombus Growth
    Alpha-dystroglycan plays functional roles in platelet aggregation and thrombus growth by Reid Gallant A thesis submitted in conformity with the requirements For the degree of Master of Science Graduate Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by Reid Gallant 2017 i Alpha-dystroglycan Plays Functional Roles in Platelet Aggregation and Thrombus Growth Reid Gallant Master of Science Department of Laboratory Medicine and Pathobiology University of Toronto 2017 ABSTRACT Fibrinogen (Fg) and von Willebrand factor (VWF) have been considered essential for platelet adhesion and aggregation. However, platelet aggregation still occurs in mice lacking Fg and/or VWF but not β3 integrin, suggesting other, unidentified αIIbβ3 integrin ligand(s) mediate platelet aggregation. Through screening published platelet proteomics data, we identified a candidate, alpha-dystroglycan (α-DG). Using Western blot and flow cytometry, I found α-DG is expressed on platelets. Using aggregometry, I observed that antibodies against α-DG or its N- terminal Laminin-binding site, decreased platelet aggregation induced by various platelet agonists in both platelet-rich plasma and gel-filtered platelets. These antibodies also decreased platelet adhesion/aggregation in perfusion chambers independent of α-DG-Laminin interaction. Using laser injury intravital microscopy and carotid artery thrombosis models, we further found that these anti-α-DG antibodies decreased thrombus growth in vivo. Our results showed that α- DG may form an α-DG-fibronectin complex that binds to αIIbβ3 integrin, contributing to platelet adhesion/aggregation, and thrombosis growth. ii Acknowledgements ―It helps a man immensely to be a bit of a hero-worshipper, and the stories of the lives of the masters of medicine do much to stimulate our ambition and rouse our sympathies‖ – Sir William Osler I will always be grateful to my MSc supervisor, Dr.
    [Show full text]
  • 32 Mechanism of Thrombosis in Antiphospholipid Syndrome: Binding to Platelets Joan-Carles Reverter and Dolors Tàssies
    32 Mechanism of Thrombosis in Antiphospholipid Syndrome: Binding to Platelets Joan-Carles Reverter and Dolors Tàssies Introduction Antiphospholipid antibodies (aPL) are related to thrombosis in the antiphospho- lipid syndrome (APS) [1, 2] and numerous pathophysiological mechanisms have been suggested involving cellular effects, plasma coagulation regulatory proteins, and fibrinolysis [3, 4]: aPL may act as blocking agents directly inhibiting antigen enzymatic or co-factor function of hemostasis; may bind fluid-phase antigens of hemostasis involved proteins and then decrease plasma antigen levels by clearance of immune complexes; may form immune complexes with their antigens that may be deposited in blood vessels causing inflammation and tissue injury; may cause dysregulation of antigen–phospholipid binding due to cross-linking of membrane bound antigens; and may trigger cell mediated events by cross-linking of antigen bound to cell surfaces or cell surface receptors [3, 4]. Moreover, several characteris- tics of the aPL, such as the concentration, class/subclass, affinity or charge, and several characteristics of the antigens, as the concentration, size, location or charge, may influence which of the theoretical autoantibody actions will occur in vivo [3]. Among the cellular mechanisms supposed to be involved, platelets have been considered as one of the most promising potential target for circulating aPL that may cause antibody mediated thrombosis as a part of the clinical spectrum of the autoimmune disorder of the APS. In the present chapter we will focus on the inter- actions that involve aPL binding to platelet membrane or platelet membrane bound antigens. Platelets as Target for aPL Platelets play a central role in primary hemostasis involving platelet adhesion to the injured blood vessel wall, followed by platelet activation, granule release, shape change, and rearrangement of the outer membrane phospholipids and proteins, transforming them into a highly efficient procoagulant surface [5].
    [Show full text]
  • Factor V Leiden Thrombophilia
    Factor V Leiden thrombophilia Description Factor V Leiden thrombophilia is an inherited disorder of blood clotting. Factor V Leiden is the name of a specific gene mutation that results in thrombophilia, which is an increased tendency to form abnormal blood clots that can block blood vessels. People with factor V Leiden thrombophilia have a higher than average risk of developing a type of blood clot called a deep venous thrombosis (DVT). DVTs occur most often in the legs, although they can also occur in other parts of the body, including the brain, eyes, liver, and kidneys. Factor V Leiden thrombophilia also increases the risk that clots will break away from their original site and travel through the bloodstream. These clots can lodge in the lungs, where they are known as pulmonary emboli. Although factor V Leiden thrombophilia increases the risk of blood clots, only about 10 percent of individuals with the factor V Leiden mutation ever develop abnormal clots. The factor V Leiden mutation is associated with a slightly increased risk of pregnancy loss (miscarriage). Women with this mutation are two to three times more likely to have multiple (recurrent) miscarriages or a pregnancy loss during the second or third trimester. Some research suggests that the factor V Leiden mutation may also increase the risk of other complications during pregnancy, including pregnancy-induced high blood pressure (preeclampsia), slow fetal growth, and early separation of the placenta from the uterine wall (placental abruption). However, the association between the factor V Leiden mutation and these complications has not been confirmed. Most women with factor V Leiden thrombophilia have normal pregnancies.
    [Show full text]
  • Factor V Leiden Thrombophilia Jody Lynn Kujovich, MD
    GENETEST REVIEW Genetics in Medicine Factor V Leiden thrombophilia Jody Lynn Kujovich, MD TABLE OF CONTENTS Pathogenic mechanisms and molecular basis.................................................2 Obesity ...........................................................................................................8 Prevalence..............................................................................................................2 Surgery...........................................................................................................8 Diagnosis................................................................................................................2 Thrombosis not convincingly associated with Factor V Leiden....................8 Clinical diagnosis..............................................................................................2 Arterial thrombosis...........................................................................................8 Testing................................................................................................................2 Myocardial infarction.......................................................................................8 Indications for testing......................................................................................3 Stroke .................................................................................................................8 Natural history and clinical manifestations......................................................3 Genotype-phenotype
    [Show full text]
  • Thrombosis and Embolism After Injury J Clin Pathol: First Published As 10.1136/Jcp.S3-4.1.86 on 1 January 1970
    J. clin. Path., 23, Suppl. (Roy. Coll. Path.), 4, 86-101 Thrombosis and embolism after injury J Clin Pathol: first published as 10.1136/jcp.s3-4.1.86 on 1 January 1970. Downloaded from S. SEVITT From the Birmingham Accident Hospital Thrombosis is frequent in injured patients. It classified as follows, namely, local thrombosis, takes different forms, and at least one of them, deep vein thrombosis, pulmonary microem- deep vein thrombosis in the lower limbs, is a bolism, glomerular microthrombosis, allied to common cause of morbidity and death through the Schwartzman reaction, occasional cases of embolic detachment. The different kinds may be arterial thrombosis, and rarely, abacterial vege- tative endocarditis. Thrombi form in flowing blood and are layered structures, unlike blood clots which form copyright. in static blood. They contain platelets, fibrin, red cells, and leucocytes, or a variable mixture, the differences depending on size, genesis, age, and venous or arterial location; but whatever the origin, the building blocks of enlarging thrombi are closely packed clumps of platelets with narrow fibrin borders (Fig. 1). Two main pro- http://jcp.bmj.com/ cesses are involved, namely, coagulation and platelet aggregation. These are interlinked and local release of thrombin is probably the key factor; thrombin promotes platelet clumping at a low concentration and fibrin formation at a higher concentration. Further, the release of substances from platelets can set in motion the coagulation on September 30, 2021 by guest. Protected process. Local Thrombosis and Haemostasis Thrombosis is frequent as a direct response to injury. In burned skin, for example, small venous thrombi may become prominent in the subdermis and subcutaneous tissue.
    [Show full text]
  • Congenital Thrombophilia
    Congenital thrombophilia The term congenital thrombophilia covers a range of Factor V Leiden and pregnancy conditions that are inherited by someone at birth. This means It is important that women with Factor V Leiden who are that their blood is sticker than normal, which increases the pregnant discuss this with their obstetrician as they have an risk of blood clots and thrombosis. increased risk of venous thrombosis during pregnancy. Some Factor V Leiden and Prothrombin 20210 are the most evidence suggests that they may also have a slightly higher common thrombophilias among people of European origin. risk of miscarriage and placental problems. Other congenital thrombophilias include Protein C Deficiency, Protein S Deficiency, and Antithrombin Deficiency. Prothrombin 20210 Prothrombin is one of the blood clotting factors. It circulates Factor V Leiden in the blood and when activated, is converted to thrombin. Factor V Leiden is by far the most common congenital Thrombin causes fibrinogen, another clotting factor, to thrombophilia. In the UK it is present in 1 in 20 individuals of convert to fibrin strands, which make up part of a clot. European origin. It is rare in people of Black or Asian origin. The condition known as Prothrombin 20210 is due to a Factor V Leiden is caused by a change in the gene for Factor mutation of the prothrombin gene. Individuals with the V, which helps the blood to clot. To stop a clot spreading a condition tend to have slightly stickier blood, due to higher natural blood thinner, known as Protein C, breaks down prothrombin levels. Factor V.
    [Show full text]